Press release
Announce Strategic Partnership to Enhance Access to High-Quality Antibodies
Cambridge - August 28th 2025 - Antibodies.com, a trusted provider of high-quality antibodies and research reagents, is proud to announce a strategic partnership with Carl Roth, a leading supplier of laboratory and research chemicals. This collaboration represents an important milestone, expanding access to Antibodies.com's cutting-edge portfolio for Carl Roth's customers across Europe.Through this partnership, Carl Roth will distribute Antibodies.com's extensive collection of antibodies and immunoassays - including monoclonal, polyclonal, and recombinant products - designed to meet the needs of researchers in academia, biotechnology, and the pharmaceutical industry. With a strong reputation for quality, reliability, and affordability, Antibodies.com complements Carl Roth's mission to deliver best-in-class solutions for scientific discovery.
"We are excited to partner with Carl Roth, a company that shares our dedication to advancing scientific research," said Sebastian Newlove, Co-Founder of Antibodies.com. "Together, we aim to make high-quality antibodies more accessible, enabling researchers to achieve their goals with confidence and efficiency."
Dr. Leonie Hacker, Head of Product Management Chemistry & Life Science at Carl Roth, added: "This partnership represents a significant step forward in our commitment to empowering researchers with the best tools available. By integrating Antibodies.com's high-quality antibodies into our offerings, we are ensuring that our customers have access to innovative products at fair prices, supporting their groundbreaking work in life sciences."
Antibodies.com's customer-focused approach - emphasising transparency, rigorous quality control, and exceptional value - combined with Carl Roth's established distribution network, will streamline access to these products, ensuring seamless delivery and support for researchers across Europe.
This collaboration underscores the shared vision of both companies: to foster innovation and excellence within the scientific community. Researchers can now explore Antibodies.com's antibody portfolio through Carl Roth's online platform or by contacting their sales representatives for tailored support.
For more information about this partnership or to browse the expanded product offerings, visit www.antibodies.com [http://www.antibodies.com/?utm_source=chatgpt.com] or www.carlroth.com [http://www.carlroth.com/?utm_source=chatgpt.com].
About Carl Roth
Carl Roth, headquartered in Karlsruhe, Germany, is a leading distributor of laboratory supplies, chemicals, and equipment. With a legacy of excellence spanning decades, Carl Roth serves researchers and professionals in life sciences, chemistry, and beyond, delivering high-quality products and exceptional customer service.
About Antibodies.com
Antibodies.com is a global provider of high-quality antibodies and research reagents, dedicated to supporting scientific discovery. With a focus on affordability, reliability, and innovation, Antibodies.com empowers researchers with the tools they need to advance their work in immunology, oncology, and other critical fields.
Media Contact
Company Name: antibodies.com
Contact Person: Christian Lautenschlager
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=announce-strategic-partnership-to-enhance-access-to-highquality-antibodies]
Phone: + 44 (0)1223 298 875
Country: United Kingdom
Website: http://Antibodies.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Announce Strategic Partnership to Enhance Access to High-Quality Antibodies here
News-ID: 4162789 • Views: …
More Releases from ABNewswire
DermaStation Skin Clinic strengthens its hair loss treatment offering
The Delhi-based skin clinic offers the most advanced hair loss treatment that ensures healthier hair regrowth and improved density.
In view of the growing concerns over progressive hair fall and pattern baldness, DermaStation, a popular dermatology clinic in Delhi, enhances its Platelet Rich Plasma Therapy for better and lasting results.
The move to offer advanced platelet rich plasma treatment [https://www.dermastation.com/blog/platelet-rich-plasma-treatment-in-delhi-a-complete-guide-to-prp-therapy/] and comprehensive treatment is in line with DermaStation's commitment to provide finest…
Grand Prairie-Based Cannon System Design Addresses Rising IT Networking Demands …
Cannon System Design, a Grand Prairie technology firm established in 2019, provides IT infrastructure and security solutions across the DFW region, serving schools, hospitals, churches, and businesses with local expertise.
As businesses and institutions across the Dallas-Fort Worth area face increasing technological demands, Cannon System Design [https://www.cannonsystem.design/] has positioned itself as a reliable provider of comprehensive technology solutions. Since launching operations in 2019, the Grand Prairie-based company has been serving schools,…
CLAIMED BY GOD DESIGNS Announces 2026 Expansion Following Breakthrough Holiday P …
After achieving record holiday sales, CLAIMED BY GOD DESIGNS prepares major 2026 expansion plans to meet growing demand for faith-based fashion that empowers believers worldwide. The brand's scripture-rooted designs and innovative approach to Christian lifestyle retail continue attracting new generations of faithful consumers seeking authentic, stylish expressions of belief.
CLAIMED BY GOD DESIGNS is leveraging extraordinary holiday season success to launch ambitious expansion plans for 2026, positioning the brand to meet…
Burbank Chimney Services Advises Homeowners on Year-Round Chimney Safety
Burbank Chimney Services is advising homeowners to take a proactive approach to chimney safety during the winter heating season, when increased fireplace use can reveal underlying issues within chimney and ventilation systems. Industry professionals say colder temperatures and heavier usage often make debris accumulation, moisture intrusion, and airflow problems more noticeable and potentially hazardous.
Homeowners scheduling a Chimney Sweep [https://burbankchimneyservices.com/] are encouraged to arrange inspections during winter months, when creosote buildup,…
More Releases for Antibodies
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Arthritis Monoclonal Antibodies Market Report 2024 - Arthritis Monoclonal Antibo …
"The Business Research Company recently released a comprehensive report on the Global Arthritis Monoclonal Antibodies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The arthritis monoclonal antibodies…
Global Multispecific Antibodies Market Size Antibodies Sales Forecast 2029
Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029 Report Highlights:
• Global & Regional Market Analysis
• Global Multispecific Antibodies Market Opportunity: > USD 40 Billion
• Global Multispecific Antibodies Market Sales In 2023: > USD 8 Billion
• Number Of Approved Multispecific Antibodies: 14
• Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight
• Approved Antibodies Dosage & Pricing Insight
• Number Of Multispecific Antibodies: In Clinical Trials: > 900
• Comprehensive Insight On All Antibodies In Clinical Trials By…
Global Bispecific Antibody Market Size Bispecific Antibodies Clinical Trials FDA …
Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights:
• Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
• Global Bispecific Antibodies Market Size Yearly and Quarterly Sales (2018 till 2023)
• Global Bispecific Antibodies Market Size 2023: > USD 8 Billion
• Global Bispecific Antibodies Market Forecast Till 2029
• Approved Bispecific Antibodies Yearly and Quarterly Sales (2018 till 2023)
• Approved Bispecific Antibodies Regional Sales (2018 till 2023)
• Clinical and Commercial Insight On Approved…
Emergence of Tetravalent Antibodies
The emergence of tetravalent antibodies represents a significant advancement in the field of therapeutic antibodies, offering new possibilities for treating complex diseases such as cancer, infectious diseases, and autoimmune disorders. These innovative molecules, capable of binding to four antigens or epitopes simultaneously, provide enhanced specificity, efficacy, and versatility, addressing the limitations of traditional monoclonal and even bispecific antibodies.
Download Bispecific, Trispecific and Tetraspecific Antibodies Report:
https://www.kuickresearch.com/ccformF.php?t=1721642510
Tetravalent antibodies are designed to engage…
